GGrantIndex
← Search

USE OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN A THYROID CANCER PT

$22,433M01FY2000RRNIH

University Of New Mexico, Albuquerque NM

Investigators

Linked publications & trials

Abstract

The objective of this study is to use human recombinant human thyroid stimulating hormone, Thyrogen (Genzyme Corporation), an investigational drug, as a compassionate use therapy in a patient with metastatic papillary cancer of the thyroid.

View original record on NIH RePORTER →